Clinical trials: Drug Drug Interaction Study
Hepatitis C, HIV
Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment
This research is being done to find out whether abacavir (Ziagen®) lowers the levels of ribavirin (Ribapak®) in the body of persons taking these two drugs.
- Trial name
- NCT01052701
- Testing
- Ribavirin, Ribavirin plus Abacavir (ABC)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Johns Hopkins University
Healthy
Drug-Drug Interaction Study Between Colchicine and Atorvastatin
Colchicine is a substrate for cytochrome P450 3A4 (CYP3A4). In-vitro studies have indicated that the ortho-and para-hydroxylated metabolites of atorvastatin may be CYP3A4/5 competitive and mechanism-based inhibitors (MBI).
- Trial name
- NCT00960323
- Testing
- Colchicine, Atorvastatin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Healthy
A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
The purpose of this study is to study the effect of lanabecestat on how the body absorbs and processes 3 other medications, midazolam, simvastatin and donepezil and how these 3 medications affect lanabecestat when they are taken…
- Trial name
- NCT02406261
- Testing
- Lanabecestat, Simvastatin, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Unspecified Adult Solid Tumor, Protocol Specific
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
This clinical trial studies capecitabine and celecoxib in treating patients with solid malignancies that are metastatic or cannot be removed by surgery.
- Trial name
- NCT01705106
- Testing
- capecitabine, celecoxib, pharmacological study
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Chicago
Hepatitis C, HIV
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
This study consists of 2 parts, Part A and Part B. Part A, the Phase 1 drug interaction/early viral kinetic study, will evaluate the effect of selected antiretroviral therapies on the safety, viral kinetics, and pharmacokinetics…
- Trial name
- NCT01565889
- Testing
- SOF, EFV/FTC/TDF, EFV
- Where
- Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Gilead Sciences
Healthy
Drug-Drug Interaction Study of Qualaquin and Midazolam
This is an open label non-randomized single sequence, single group two way drug interaction study in healthy adult volunteers to determine the extent to which quinine, an inducer of cytochrome p450 CYP 3A4, affects the…
- Trial name
- NCT00785486
- Testing
- Midazolam Alone, Qualaquin (quinine) alone steady state, Midazolam and Qualaquin at steady state
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Healthy Participants
A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
This is a Phase 1, open-label, multiple dose, single fixed-sequence, 2-period study to evaluate the effect of abrocitinib on the pharmacokinetics (PK) of caffeine, efavirenz and omeprazole in healthy adult participants.
- Trial name
- NCT05067439
- Testing
- Abrocitinib, Omeprazole, Caffeine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Disease, Tuberculosis, Pulmonary
A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults
A Phase 1, Drug-Drug Interaction Study to Evaluate the Safety, Tolerability, and the Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and the Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adult Subjects
- Conditions
- Pulmonary Disease, Tuberculosis, Pulmonary, Tuberculosis, Multi Drug Resistant Tuberculosis
- Trial name
- NCT05526911
- Testing
- TBAJ-876, Midazolam, Digoxin
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Global Alliance for TB Drug Development
Psoriasis
Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects
This is a phase 1, multi-center, open-label, drug-drug interaction (DDI) and PK study in subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT01937260
- Testing
- Brodalumab
- Where
- 10 sites in United States, Australia and 1 more
- Volunteers
- 31 people
- Sponsor
- Bausch Health Americas, Inc.
Cancer
A Drug Interaction Study to Assess the Effect of LY2603618 on the Metabolic Pathway of Desipramine
The purpose of this study is to assess the effect LY2603618 on a protein [enzyme cytochrome P (CYP) 2D6] which is involved in the metabolic pathway of Desipramine in participants with cancer.
- Trial name
- NCT01358968
- Testing
- LY2603618, Desipramine, Pemetrexed
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
HIV
Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection
The purpose of this study is to assess the effects of famotidine, given twice daily, on atazanavir administered with ritonavir and tenofovir in HIV-infected participants.
- Trial name
- NCT01232127
- Testing
- Atazanavir, Ritonavir, Tenofovir (TDF)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb
Drug-drug Interaction Study
A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin
The goal of this clinical study was to determine the effect of the test drug ceftobiprole (a drug approved for the treatment of bacterial infections) on the elimination of pitavastatin (a drug approved for the treatment of…
- Trial name
- NCT06808646
- Testing
- pitavastatin, pitavastatin single dose combined with ceftobiprole
- Where
- Netherlands
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Healthy Volunteers
Drug Interaction Study of Lopinavir/Ritonavir and Gemfibrozil
This study will determine whether the protease inhibitor lopinavir/ ritonavir (Kaletra (Trademark)), which is used to treat HIV disease, lowers blood levels of the lipid-regulating drug gemfibrozil (Lopid (Trademark)) in…
- Trial name
- GEM-PK (NCT00474201)
- Testing
- Lopinavir/Ritonavir, Gemfibrozil
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National Institutes of Health Clinical Center (CC)
Healthy
An Interaction Study to Assess Drug Levels in Healthy Adult Subjects
To date, no study has investigated whether there is a drug interaction between the protease inhibitor fosamprenavir and the integrase inhibitor raltegravir.
- Trial name
- NCT00614991
- Testing
- Raltegravir, Fosamprenavir, Ritonavir
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Garden State Infectious Disease Associates, PA
Healthy
A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants
The main purpose of this study is to determine the effect of selpercatinib on the levels of dabigatran in the blood stream and how long it takes the body to remove dabigatran.
- Trial name
- NCT04782076
- Testing
- Dabigatran, Selpercatinib
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Loxo Oncology, Inc.
Pharmacokinetics
Drug-Drug Interaction Study of Colchicine and Azithromycin
Azithromycin is a possible weak to moderate inhibitor of CYP3A4, one of the enzymes responsible for the metabolism of colchicine.
- Trial name
- NCT00983294
- Testing
- Colchicine, Azithromycin
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Drug Interaction
PPI and Clopidogrel Response
Clopidogrel, in combination with aspirin, is currently the recommended treatment for secondary prevention of ischemic events in high-risk patients and for prevention of coronary artery stent thrombosis.
- Trial name
- NCT01170533
- Testing
- omeprazole and pantoprazole
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Florida
Healthy
An Interaction Study to Assess Drug Levels in Healthy Adult Subjects
To date, no study has investigated whether there is a drug interaction between the protease inhibitor fosamprenavir and the entry inhibitor maraviroc.
- Trial name
- NCT00764465
- Testing
- Maraviroc, Fosamprenavir, Ritonavir
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Garden State Infectious Disease Associates, PA
Pharmacokinetics, Safety
JOTROL PK, Safety, and Food Effect Assessment
Type of Study: Single Ascending Doses (SAD) Study Objectives: To characterize the pharmacokinetic (PK) profile of JOTROL (resveratrol) following oral administration of SAD ranging from 200 mg up to a dose currently estimated at…
- Conditions
- Pharmacokinetics, Safety, Food-drug Interaction
- Trial name
- NCT04668274
- Testing
- 200 mg resveratrol as JOTROL, 500 mg resveratrol as JOTROL, 700 mg resveratrol as JOTROL
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jupiter Orphan Therapeutics Inc.
Healthy
Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects
The objective of the study is to assess the relative bioavailability of a single dose of dabigatran after concomitant multiple oral administration of dronedarone with the aim to investigate whether and to what extent the P-gp…
- Trial name
- NCT01306162
- Testing
- Dabigatran etexilate plus dronedarone, Dabigatran etexilate
- Where
- Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim